Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Retained Earnings (2016 - 2025)

Rein Therapeutics filings provide 10 years of Retained Earnings readings, the most recent being -$62000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 99.98% year-over-year to -$62000.0, compared with a TTM value of -$62000.0 through Dec 2025, up 99.98%, and an annual FY2025 reading of -$62000.0, up 99.98% over the prior year.
  • Retained Earnings hit -$62000.0 in Q4 2025 for Rein Therapeutics, up from -$369.3 million in the prior quarter.
  • The five-year high for Retained Earnings was -$2000.0 in Q2 2023, with the low at -$369.3 million in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$229.1 million (2021), compared with a mean of -$157.0 million.
  • The sharpest move saw Retained Earnings crashed 23865600.0% in 2021, then skyrocketed 99.99% in 2024.
  • Year by year, Retained Earnings stood at -$245.5 million in 2021, then dropped by 11.13% to -$272.8 million in 2022, then fell by 5.77% to -$288.5 million in 2023, then decreased by 21.8% to -$351.4 million in 2024, then surged by 99.98% to -$62000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$62000.0, -$369.3 million, and -$44000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.